Skip to content

India PanOptix Post Marketing Study

An Observational, Prospective, Post-Marketing Clinical Study of the ACRYSOF® IQ PanOptix Multifocal IOL in an Indian Population

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03706066
Enrollment
80
Registered
2018-10-15
Start date
2019-01-15
Completion date
2020-01-18
Last updated
2020-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataract

Brief summary

The purpose of this Post Marketing Study is to study the safety and effectiveness of the ACRYSOF IQ PanOptix intraocular lens (IOL) in an Indian population.

Detailed description

The study population will consist of adult Indian males and females, at least 18 years of age or older at the time of screening, with no ocular pathology that could confound study outcomes, who are advised bilateral cataract extraction and who desire an IOL that provides the potential for correction of near, intermediate, and distance vision. Both eyes will be implanted. The second eye surgery will take place 15-30 days after the first eye surgery. Subjects will be followed for approximately 3 months after the second eye surgery. Total individual subject participation will be approximately 4 months. This study will be conducted in India.

Interventions

DEVICEAcrysof IQ PanOptix IOL

Single-piece, ultraviolet and blue-light filtering, foldable, multifocal intraocular lens (IOL) inserted into the capsular bag during cataract surgery

PROCEDURECataract surgery

Per investigator's standard of care

Sponsors

Alcon Research
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Able to comprehend and willing to sign informed consent and complete all required postoperative follow-up procedures; * Advised cataract extraction in both eyes and agreed for bilateral implantation of ACRYSOF IQ PanOptix lens; * Preoperative regular keratometric astigmatism of ≤1.0 D in both eyes.

Exclusion criteria

* Pregnant or lactating, current or planned, during the course of the study; * Retinal abnormalities (Macular Degeneration, dystrophy, edema , traction or other pathologies affecting vision); * Clinically significant corneal abnormalities; * History of retinal conditions; * Previous refractive surgery, including LASIK; * Glaucoma; * Any condition that may not be appropriate to this study, as per the Investigator's expert medical opinion. Other protocol-specified inclusion and/or

Design outcomes

Primary

MeasureTime frameDescription
Best corrected binocular visual acuity at distance (4 m) at 3 months post bilateral implantationMonth 3 (following second eye surgery)Visual acuity will be assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) charts and reported in logarithm minimum angle of resolution (logMAR).

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026